Pular para conteúdo

Beta-talassemia maior (pediatria)

Indução farmacológica da síntese da hemoglobina fetal

Terapia com Hidroxiureia (Hidroxicarbamida)\_

Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (abre nova janela)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Fonte‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indexado‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (abre nova janela)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (abre nova janela)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Fonte‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indexado‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (abre nova janela)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (abre nova janela)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Fonte‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indexado‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (abre nova janela)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (abre nova janela)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Fonte‎: Blood 2003;102(4):1529-30.

Indexado‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (abre nova janela)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (abre nova janela)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Fonte‎: Transfusion 2007;47(10):1830-6.

Indexado‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (abre nova janela)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (abre nova janela)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Fonte‎: Int J Hematol 2012;95(1):51-6.

Indexado‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (abre nova janela)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (abre nova janela)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Fonte‎: Haematologica 2004;89(10):1172-8.

Indexado‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (abre nova janela)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (abre nova janela)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Fonte‎: Arch Iran Med 2009;12(3):295-7.

Indexado‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (abre nova janela)

Eritropoetina Recombinante (Isolada ou Combinada com Outros Agentes)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (abre nova janela)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Fonte‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indexado‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (abre nova janela)

Outros Agentes

Fetal globin gene inducers: novel agents and new potential. (abre nova janela)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Fonte‎: Ann N Y Acad Sci 2010;1202:158-64.

Indexado‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (abre nova janela)